EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Perrigo Company (P1RG34) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Perrigo Company BRL 48.85, price BRL 72.30, upside -32.4%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · BR · ISIN IE00BGH1M568

PC Some data Sep 24, 2026

Perrigo Company

P1RG34 · SA

Weak valuationQuality is weak on top of the rich price.

!Fair value R$48.85 · Overvalued (−32.4%)
!Quality 43/100
!Weak Growth (revenue 3y −1.5 %/yr)
!Loss-making · -43.5% net margin (TTM)
✓Moderate debt · generates free cash flow
✓1.6% dividend yield · Sustainable
!Narrow moat 19/100
!Evidence only medium, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$222.22 R$48.53 Fair Value R$48.85 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range R$48.53 – R$222.22 · fair‑value band R$45.39 – R$48.85 · the R$72.30 price screens above the R$48.85 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Show more

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Stock analysis

Perrigo Company (P1RG34) currently trades at R$72.30, while our model-based Fair Value estimate is R$48.85, 32.4% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of R$74.23 per share, and 1 of the 3 models we run sit above the R$72.30 price.

Bear case: the Dividend Discount group reads lowest at R$50.35, and 2 of the 3 models stay below the price. Evidence for this calculation is medium.

Scenario range: R$45.39 (bear) to R$48.85 (bull), the price of R$72.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Perrigo Company reported revenue of $4.3B in FY2025 versus $4.1B in FY2021, a compound +0.7%/yr. Reported net income was −$1.4B in FY2025.

Key figures

Market cap R$10.0B (≈ $1.9B) · P/S ratio 1.71 · EPS (TTM) R$−67.00 · Dividend yield 1.6% · Net margin −33.5% · Return on equity −52.2% · Return on assets (EBIT) −0.9% · Operating margin 3.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −32%, P1RG34 screens richer than that median.

Fair Value models

Bear R$45.39 Fair Value R$48.85 Bull R$48.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Growth DCF n/a n/a R$32.00 72
Gordon GGM R$46.71 R$50.35 R$55.77 67
DDM Multi-Stage R$46.71 R$55.61 R$67.08 65
All 4 models by family
Dividend Discount
Gordon GGM R$46.71 R$50.35 R$55.77 67
DDM Multi-Stage R$46.71 R$55.61 R$67.08 65
Asset-Based
NCAV (Graham) R$55.40 R$74.23 R$110.79 54
Growth DCF
Growth DCF n/a n/a R$32.00 72

Open the full fair value analysis →

Notify me when P1RG34 reaches fair value

Put P1RG34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 42 · Market factors (momentum, volatility) 45

Profitability 12
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 34
Earnings quality: real cash, not paper profit
Fin. Strength 34
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 49
Calm price path (market factor)
Momentum 60
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 74
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 19/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.5% (2021) → −27.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+0.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +24.7% a year for the price and −2.3% for the forecasts.
Forecast 2026 (sales)−4.6%
Forecast 2027 (sales)+1.0%
Projected 2028 (sales)+1.2%
Projected 2029 (sales)+1.3%
Projected 2030 (sales)+1.4%

P1RG34 screens overvalued: fair value 32% below the price. Compare with Merck KGaA →

Compare Perrigo Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Perrigo Company · Fair Value
R$48.85 −32%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Perrigo Company Fair Value". https://www.fairvalue-calculator.com/stock/P1RG34

Frequently asked questions

Is Perrigo Company (P1RG34) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of R$48.85 versus a price of R$72.30, about −32% upside (overvalued).
What is the fair value of P1RG34?
Our model-based fair value for Perrigo Company is R$48.85 (as of Sep 24, 2026), built from audited fundamentals. The current price: R$72.30.
What is the quality score of P1RG34?
Perrigo Company has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Perrigo Company (P1RG34)?
Our model-based price target is the fair value of R$48.85 (as of Sep 24, 2026) from 4 valuation models. Cautious scenario R$45.39, optimistic scenario R$48.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Perrigo Company stock forecast for 2026?
Our models put fair value at R$48.85, about −32% upside versus a price of R$72.30 (overvalued). Cautious scenario R$45.39, optimistic scenario R$48.85. The calculation is refreshed regularly with new filings.
What is the revenue of Perrigo Company (P1RG34)?
Perrigo Company reported trailing-twelve-month revenue of about $4.2B (latest available figure, as of Sep 24, 2026).
Does Perrigo Company pay a dividend?
Perrigo Company currently shows a dividend yield of about 1.60% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Perrigo Company (P1RG34)?
For today's price to be fair in a discounted-cash-flow model, Perrigo Company would have to grow free cash flow by +27.7 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +0.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of P1RG34 use?
Our models discount Perrigo Company at 12.7 %: a base by market capitalisation (small), damped by beta 0.52, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Perrigo Company that is +27.7 % per year a year over ten years, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has Perrigo Company (P1RG34) delivered so far?
Over the past 4 years revenue at Perrigo Company grew +0.7 % a year. The price currently implies +27.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Perrigo Company (P1RG34) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Perrigo Company (+27.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Perrigo Company (P1RG34)?
The free-cash-flow yield on the price is 7.62 %: that much free cash flow Perrigo Company produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Perrigo Company (P1RG34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Perrigo Company it is R$48.85 per share (as of Sep 24, 2026), against a price of R$72.30. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Perrigo Company stock overvalued or undervalued in 2026?
As of Sep 24, 2026, P1RG34 trades above its calculated fair value: price R$72.30, fair value R$48.85, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of P1RG34?
No. The price is what the market pays today (R$72.30); the fair value is what the company's own numbers justify (R$48.85). For Perrigo Company the two are R$23.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Perrigo Company worth?
The market values Perrigo Company at about R$10.0B (market capitalisation, as of Sep 24, 2026). Per share that is R$72.30; our models calculate a fair value of R$48.85 per share.
What do the bullish and bearish scenarios say about P1RG34?
Our models span a range for Perrigo Company: cautious scenario R$45.39, base R$48.85, optimistic R$48.85 per share (as of Sep 24, 2026, price R$72.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is P1RG34 from its 52-week high?
Perrigo Company trades at R$72.30, about 37% below its 52-week high of R$114.48 and 49% above the low of R$48.53 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of R$48.85 is for.
Which stocks are comparable to Perrigo Company?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Perrigo Company stock attractive at the current price?
The data as of Sep 24, 2026: price R$72.30, calculated fair value R$48.85 (−32%), Quality Score 43/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of P1RG34 calculated?
We run Perrigo Company through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$48.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Perrigo Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Perrigo Company (P1RG34)?
The closing price on Oct 1, 2026 was R$72.30. Our model-based fair value is R$48.85, about −32% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Perrigo Company right now?
The price sits above even our optimistic bull case (R$48.85). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (R$45.39 to R$48.85), unusually little disagreement for a valuation.

Key figures of Perrigo Company

How large is the market capitalisation of Perrigo Company (P1RG34)?
The market capitalisation of Perrigo Company is R$10.0B (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Perrigo Company (P1RG34)?
The price-to-sales ratio of Perrigo Company is 1.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Perrigo Company (P1RG34)?
Earnings per share at Perrigo Company are R$−67.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Perrigo Company (P1RG34)?
The dividend yield of Perrigo Company is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Perrigo Company (P1RG34)?
The net margin of Perrigo Company is −33.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Perrigo Company (P1RG34)?
The return on equity (ROE) of Perrigo Company is −52.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Perrigo Company (P1RG34)?
On an EBIT basis the return on assets of Perrigo Company is −0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Perrigo Company (P1RG34)?
The operating margin of Perrigo Company is 3.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Perrigo Company (P1RG34)?
Revenue at Perrigo Company is growing −7.2% versus a year earlier (3y avg −1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Perrigo Company (P1RG34) carry?
The net debt of Perrigo Company is $3.1B (fiscal year 2025, ≈ 21.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.